Cita APA (7a ed.)
Marković, F., Stjepanović, M., & Kontić, M. (2026). Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact. Current Oncology, 31(2), 109-122.
Cita Chicago Style (17a ed.)
Marković, Filip, Mihailo Stjepanović, y Milica Kontić. "Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact." Current Oncology 31, no. 2 (2026): 109-122.
Cita MLA (9a ed.)
Marković, Filip, et al. "Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact." Current Oncology, vol. 31, no. 2, 2026, pp. 109-122.
Precaución: Estas citas no son 100% exactas.